Patents by Inventor Aitor Nogales

Aitor Nogales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-influenza neuraminidase monoclonal antibodies and uses thereof
    Patent number: 11958895
    Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: April 16, 2024
    Assignee: University of Rochester
    Inventors: James J. Kobie, Luis Martinez-Sobrido, Michael Piepenbrink, Aitor Nogales
  • MONOCLONAL ANTIBODIES AGAINST THE HEMAGGLUTININ (HA) AND NEURAMINIDASE (NA) OF INFLUENZA H3N2 VIRUSES
    Publication number: 20230107644
    Abstract: The present disclosure relates to neutralizing anti-influenza monoclonal antibodies. The disclosure further relates to therapeutic uses of the isolated antibody. The antibodies are either directed against Hemagglutinin (HA) and Neuraminidase (NA) of Influenza H3N2.
    Type: Application
    Filed: March 25, 2021
    Publication date: April 6, 2023
    Applicant: University of Rochester
    Inventors: James J. Kobie, Luis Martinez-Sobrido, Michael Piepenbrink, Aitor Nogales
  • Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
    Patent number: 11168129
    Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: November 9, 2021
    Assignee: University of Rochester
    Inventors: James J. Kobie, Michael Piepenbrink, Michael Keefer, Luis Martinez-Sobrido, Aitor Nogales
  • Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
    Patent number: 11065326
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that various mutations in segment 1 and segment 2 of the CIV genome, thereby encoding mutant PB2 and PB1 protein, render the virus to be temperature-sensitive.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: July 20, 2021
    Assignees: University of Rochester, Cornell University
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • NS1 truncated virus for the development of canine influenza vaccines
    Patent number: 10973903
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based on the development of mutant CIV, having one or more mutations in segment 8, which induces a CIV-specific immune response in a subject.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 13, 2021
    Assignees: University of Rochester, Cornell University
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • ANTI-INFLUENZA NEURAMINIDASE MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20210047389
    Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.
    Type: Application
    Filed: May 2, 2019
    Publication date: February 18, 2021
    Inventors: James J. Kobie, Luis Martinez-Sobrido, Michael Piepenbrink, Aitor Nogales
  • NS1 Truncated Virus for the Development of Canine Influenza Vaccines
    Publication number: 20200206341
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based on the development of mutant CIV, having one or more mutations in segment 8, which induces a CIV-specific immune response in a subject.
    Type: Application
    Filed: August 19, 2016
    Publication date: July 2, 2020
    Inventors: Luis Martinez-Sobrido, Aitor NOGALES-GONZALEZ, Colin PARRISH
  • Broadly Neutralizing Anti-Influenza Human Monoclonal Antibody and Uses Thereof
    Publication number: 20200140526
    Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.
    Type: Application
    Filed: May 10, 2018
    Publication date: May 7, 2020
    Applicant: University of Rochester
    Inventors: James J. Kobie, Michael Piepenbrink, Michael Keefer, Luis Martinez-Sobrido, Aitor Nogales
  • Single-cycle virus for the development of canine influenza vaccines
    Patent number: 10548966
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that one or more mutations in segment 4 of the viral genome produces a single cycle infectious CIV (sciCIV). The sciCIV does not allow for the production of infectious progeny, but is able to induce a CIV-specific immune response.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: February 4, 2020
    Assignees: UNIVERSITY OF ROCHESTER, CORNELL UNIVERSITY
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • Live-Attenuated Vaccine Having Mutations in Viral Polymerase for the Treatment and Prevention of Canine Influenza Virus
    Publication number: 20200023055
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that various mutations in segment 1 and segment 2 of the CIV genome, thereby encoding mutant PB2 and PB1 protein, render the virus to be temperature-sensitive.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 23, 2020
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
    Patent number: 10478489
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that various mutations in segment 1 and segment 2 of the CIV genome, thereby encoding mutant PB2 and PB1 protein, render the virus to be temperature-sensitive.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 19, 2019
    Assignees: University of Rochester, Cornell University
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • Single-Cycle Virus for the Development of Canine Influenza Vaccines
    Publication number: 20180256703
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that one or more mutations in segment 4 of the viral genome produces a single cycle infectious CIV (sciCIV). The sciCIV does not allow for the production of infectious progeny, but is able to induce a CIV-specific immune response.
    Type: Application
    Filed: August 19, 2016
    Publication date: September 13, 2018
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • Live-Attenuated Vaccine Having Mutations in Viral Polymerase for the Treatment and Prevention of Canine Influenza Virus
    Publication number: 20180243401
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that various mutations in segment 1 and segment 2 of the CIV genome, thereby encoding mutant PB2 and PB1 protein, render the virus to be temperature-sensitive.
    Type: Application
    Filed: August 19, 2016
    Publication date: August 30, 2018
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish